<DOC>
	<DOCNO>NCT00518557</DOCNO>
	<brief_summary>The purpose study investigate safety potential therapeutic benefit patient hepatocellular carcinoma transcatheter chemoembolization recombinant endostatin ( commercially available China ) also administrate via hepatic artery . The hypothesis protocol TACE antiangiogenic treatment may inhibit proangiogenic effect induce hypoxia TACE .</brief_summary>
	<brief_title>Synergistic Treatment Hepatocellular Carcinoma ( HCC ) Using TACE With Antiangiogenesis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients cytologically histologically document HCC , candidate TACE ChildPugh Child A B Age &gt; = 18 Measurable disease RECIST criterion ; Performance status ECOG 02 Previous local therapy complete &gt; 4 week Written inform consent sign Normal organ marrow function define : Haematopoietic : WBC ≥ 3,000/µlplatelet count &gt; 80,000/mm3 haemoglobin &gt; 9g/dL Hepatic : Albumin ≥ 2.8 g/dl.serum total bilirubin ≤ 3 mg/dl ; AST ALT &lt; 5 x ULN Renal : creatinine &lt; 1.5 x ULN Metastases Prior concomitant chemotherapy radiation therapy VEGF/VEGFR inhibitor antiangiogenesis agent Severe and/or uncontrolled medical condition : Congestive heart failure , serious cardiac arrhythmia , active coronary artery Severe renal impairment Patients anticipate receive major surgery course Pregnant breastfeeding patient Evidence bleed diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>interventional radiology</keyword>
	<keyword>Chemoembolization</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
</DOC>